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Abstract
Purpose To summarize the impact of tuberculosis (TB)
on quantitative measures on self-reported health-related
quality of life (HRQOL).
Methods We searched eight databases to retrieve all peer-
reviewed publications reporting original HRQOL data for
persons with TB. All retrieved abstracts were considered for
full-text review if HRQOL was quantitatively assessed
among subjects with TB. Full-text articles were reviewed by
two independent reviewers using a standardized abstraction
form to collect data on socio-demographic characteristics,
questionnaire administration, and mean HRQOL scores.
Meta-analyses were performed for standardized mean dif-
ferences in HRQOL scores, comparing subjects treated for
active TB with subjects treated for latent TB infection
(LTBI), or with healthy controls, at similar time points with
respect to diagnosis and/or treatment.
Results From over 15,000 abstracts retrieved, 76 full-text
articles were reviewed, which represented 28 unique
cohorts (6,028 subjects) reporting HRQOL among subjects
with active TB; 42 % were women and mean age was
42 years. Data on key social and behavioral determinants
were limited. Within individual studies and in meta-anal-
yses, subjects with active TB disease consistently reported
worse HRQOL than concurrently evaluated subjects treated
for LTBI. However, meaningful improvements in HRQOL
throughout active TB treatment were reported by longitu-
dinal studies.
Conclusions In a variety of studies, in different settings
and using different instruments, subjects with active TB
consistently reported poorer HRQOL than persons treated
for LTBI. Future research on HRQOL and TB should better
address social and behavioral health determinants which
may also affect HRQOL.
Keywords Tuberculosis  Health-related quality of life 
Systematic review  Meta-analysis
Introduction
One-third of the world’s population is infected with
Mycobacterium tuberculosis, which causes the infectious
respiratory disease tuberculosis (TB) [34]. In 2010, the
World Health Organization (WHO) estimated 8.8 million
new cases of TB, and 1.1 million deaths from TB among
HIV-negative individuals [11, 54].
Active TB disease exerts a substantial toll on quality of
life—ranging from somatic symptoms related to disease
and treatment to psychological distress from social isola-
tion and stigmatization [18, 25, 47]. The diagnosis of latent
TB infection (LTBI) may be misconstrued as active TB
disease or even HIV infection, both of which may also lead
to further stigmatization; in some communities, the diag-
nosis of TB is strongly associated with HIV infection [36,
50, 58]. Health-related quality of life (HRQOL), as repor-
ted by patients, is therefore highly relevant to under-
standing and quantifying the true impact of TB.
The purpose of this research is to summarize the impact
of TB on quantitative measures of self-reported HRQOL.
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We have conducted a systematic review of self-reported
HRQOL among persons with active TB, LTBI, and those
with persistent pulmonary symptoms following treatment
of active TB. This updates and supplements a previous
systematic review, which addressed HRQOL among TB
patients, by expanding the search strategy and searching
more databases [22].
Methods
Identification and selection of relevant publications
and research
A librarian trained in systematic reviews of medical liter-
ature was consulted to construct a comprehensive search
strategy. Terms included in the search strategy related to
the concepts of the operational definition of HRQOL as
described by Wilson and Cleary [55]. We searched 8 dat-
abases to retrieve relevant peer-reviewed publications,
reporting original research: PubMed, EMBASE, EMBASE
classic, PsycINFO, HaPI, BIOSIS, The Cochrane Library,
and CINAHL. Databases were searched for articles pub-
lished between January 1, 1960 and April 1, 2011. The
search strategy is provided in ‘‘Appendix 1’’.
All retrieved abstracts were exported to EndNote X4
software and screened by one author (MB); any abstract
that reported self-rated, quantitative measures of HRQOL
among TB subjects was eligible for full review. Two
authors, fluent in English, read full-text versions of all
articles written in English and completed a standardized
abstraction form for all studies that evaluated HRQOL
among individuals with active TB, LTBI, or post-TB pul-
monary sequelae. Abstracted information was reviewed
and discrepancies discussed between these two reviewers.
If a discrepancy arose, the two authors reviewed the ori-
ginal article together to reach consensus. For those articles
published in a language other than English, other research
personnel fluent in the language of the publication, as well
as English, completed the abstraction form. References
cited among the included publications were scanned for
additional potential relevant studies, which were also
reviewed, if eligible, using the abstraction form.
Articles were excluded from the review if (1) quantita-
tive measures of HRQOL were not available or if there
were no subjects with TB included, (2) if data for subjects
with and without TB were aggregated together, (3) if the
full-text articles were not accessible to reviewers, or (4) if
the publication was written in a language that the reviewers
were unable to understand. Studies using the standard
gamble instrument were included, since it provides an
assessment of health utility, a quantitative measure of
HRQOL that incorporates uncertainty, which is particularly
relevant to health care decision makers.
Data extraction
The standardized abstraction form captured the following
information:
• socio-demographic characteristics of subjects
• clinical characteristics for subjects with active TB
(pulmonary/extra-pulmonary disease, smear status, re-
treatment)
• behavioral risks (smoking, alcohol abuse, and injection
drug use),
• study design features (subject recruitment mechanisms
and inclusion/exclusion criteria),
• accounting for subjects who were (a) eligible from the
target population, (b) approached of those eligible,
(c) recruited of those approached, (d) completed eval-
uations of those recruited, and (e) included in the
analysis of those who completed evaluations,
• HRQOL questionnaire administration (subject self-
administered/interviewer-administered, language of
administration, timing with respect to TB diagnosis
and treatment, proxy respondents), and
• HRQOL results, by subject group
The abstraction form also included a quality rating score
using a 3-point scale (2 being well-described, 1 poorly
described, and 0 not described in article) for each of the
following eight attributes: study population, sampling
mechanism, accounting for potential subjects not included
in the analyses, quality check of responses, explicit
description of HRQOL instruments, data entry check,
training of interviewers, and discussion of study strengths
and limitations. These eight items were extracted from the
STROBE Statement—checklist of items that should be
included in observational studies (version 4) based on
study characteristics anticipated to vary widely across
studies, with particular focus on methods and results [48].
Summary quality ratings were calculated by summing the
scores for each of these eight categories; the minimum and
maximum possible scores were 0 and 16, respectively.
Statistical analysis
Data extracted from original publications were recorded in
Microsoft Excel (2010). Demographics, disease character-
istics, and HRQOL measures were extracted and summa-
rized by sub-group (active TB, LTBI, TB-free controls,
etc.) Variables describing study design and methods were
summarized.
We used Microsoft Excel (2010) to calculate standard-
ized mean differences of HRQOL scores between the group
of subjects treated for active TB in a given study and a
concurrently evaluated comparison group. Meta-analyses
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were performed for standardized mean differences among
studies that compared similar groups and administered the
HRQOL questionnaires at similar time points with respect
to TB diagnosis and/or treatment. For those publications
that were deemed eligible for meta-analysis but did not
report the particular measure of interest, investigators were
contacted to request these data.
For each group of studies included in a given meta-
analysis, we used MIX 2.0 Pro to calculate the random
effects pooled estimates, using the DerSimonian-Laird
method, of standardized mean differences in HRQOL
scores [5, 23]. We used MIX 2.0 Pro to produce forest plots
and calculate the I2 statistics, with 95 % confidence inter-
vals (CI) [5, 23]. These statistics allowed us to assess
heterogeneity among studies’ standardized mean differ-
ences in HRQOL scores.
We used Microsoft Excel (2010) to calculate effect sizes
among studies with longitudinal measures of HRQOL,
comparing subsequent with initial measurements [8]. Any
effect size of at least 0.50 was considered a meaningful
change in HRQOL [43]. We also compared changes in
HRQOL scores to previously published estimates of min-
imum important difference for the relevant instruments,
when available.
Results
The search strategy yielded over 15,000 abstracts, 46 of
which were eligible for full-text review. We looked for
additional publications in the references of each of these 46
articles to retrieve an additional 30 articles for full-text
review (Fig. 1).
Of the 76 full-text articles, 38 (representing quantitative
HRQOL evaluations among 28 unique cohorts of TB
patients) were relevant to our review [1–4, 6, 9, 10, 12–21,
26, 29, 31–33, 35, 37, 38, 40, 41, 46, 47, 50, 52–54, 57, 58,
60, 61]. Studies included in the systematic review were
published in English, Korean, Chinese, Spanish, and
Turkish. Five unique cohorts contributed to meta-analyses;
all articles in the meta-analysis were published in English
[4, 15–17, 33, 38]. Five unique cohorts contributed to
analysis on meaningful changes in effect sizes of HRQOL
measures over time [14, 15, 29, 32, 33].
The 28 cohorts together included 6,028 subjects from 16
countries, across 5 continents. Twenty-one studies (75 %)
collected cross-sectional data, and 7 studies (25 %) studies
used a longitudinal design. There were no randomized
controlled trials conducted among TB patients that inclu-
ded quantitative, patient-reported HRQOL measures. Pri-
mary data collection for these studies occurred between
1992 and 2011.
Characteristics of all subjects
Twenty-seven of the 28 unique cohorts reported the number
of women, which corresponded to 42 % of the subjects in
these studies [1–4, 6, 9, 10, 12–15, 18–21, 26, 29, 31–33, 35,
37, 38, 39, 40, 45, 46, 49, 51–53, 56, 57, 59, 60]. Mean age
(reported in 13 studies) was the most frequently reported
summary measure of age [1–4, 6, 13–15, 20, 21, 26, 32, 33,
38, 45, 46, 52, 53, 59, 60]. Although the mean age of subjects
across these 13 studies was 42 years, the mean age ranged
from 26 to 62 years within individual studies. Among the 5
studies reporting the proportion of foreign-born subjects in
their sample, 75 % of all subjects were foreign-born, ranging
from 48 to 89 % across these studies [4, 21, 29, 33, 38]. Eight
studies stated they excluded known TB/HIV co-infected
patients or included these patients and provided sero-sta-
tus—696 (29 %) of all subjects with known sero-status were
co-infected with TB/HIV, which ranged from 0 to 100 %
across these studies [3, 4, 12, 16, 17, 26, 32, 33, 38]. Infor-
mation on subjects’ health behaviors and socioeconomic
profiles was extremely limited (Table 1).
Twenty-four of the 28 unique studies (representing
3,541 subjects, 59 % of the total sample) conducted
quantitative assessments of HRQOL among persons with
active TB [1–4, 6, 12–15, 18, 20, 21, 26, 29, 32, 33, 35, 38,
41, 46, 47, 50, 52–54, 60, 61]. Fourteen of these studies
concurrently evaluated HRQOL among other patient
groups—6 studies evaluated persons with LTBI, while 8
evaluated TB-free, healthy control subjects [1–3, 15–17,
20, 21, 33, 38, 46, 47, 52–54, 60] (Table 1).
The remaining 4 of the 28 unique studies evaluated
HRQOL among subjects with patients with post-TB
sequelae who developed chronic alveolar hypoventilation
(CAH) and were using home mechanical ventilation
(HMV); see ‘‘Appendix 4’’ and Table 7 in Appendix [9, 10,
19, 37, 40, 57, 58].
Classification of TB patient groups
Fifteen of the 24 studies evaluating HRQOL among
patients with active TB specified that disease diagnosis was
based on smear and/or culture confirmation, and/or the use
of standardized clinical and radiographic criteria (e.g.,
those of the WHO) [3, 4, 12, 15–18, 26, 29, 32, 33, 38, 46,
47, 50, 52, 53, 61]. Nineteen studies (2,586 subjects with
active TB, 73 %) specified the disease site of these sub-
jects—2,350 (91 %) had pulmonary TB; 888 (38 %) of
these individuals were sputum smear-positive at their ini-
tial HRQOL evaluation, which generally indicates more
severe and contagious disease [1–4, 12–15, 20, 26, 29, 32,
33, 35, 38, 50, 52–54, 60, 61].
A total of 639 subjects treated for LTBI (11 % of the
total sample) were concurrently evaluated in 6 studies that
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assessed HRQOL among subjects with active TB [4, 16,
17, 21, 33, 38, 46, 47]. Five of these 6 studies explicitly
stated that subjects with LTBI were diagnosed by a positive
tuberculin skin test (TST), representing 533 (88 %) of all
LTBI subjects [4, 16, 17, 33, 38, 46, 47].
A total of 1049 healthy control subjects (17 % of the
total sample) were concurrently evaluated in 8 studies that
assessed HRQOL among subjects with active TB [1, 4, 15,
20, 46, 47, 50, 52, 53, 60]. Confirmation of healthy status
was described in only 3 studies; diagnostic criteria included
a physical exam plus chest radiographs and electrocardio-
grams, and/or a negative TST result [4, 20, 46, 47].
HRQOL and health utility instruments
Thirty-four different HRQOL and health utility instruments
were used among the studies described in this review
(Table 5 in Appendix). The most commonly used tool was
15,234 titles and abstracts identified using search strategy 
in eight databases and reviewed by MB
41 full-text articles reviewed 
independently by MB and AL
5 full-text articles published in a language other than 
English and reviewed by research staff member fluent in 
the language of publication
28 full-text articles 
referenced by 





15,188 abstracts and titles 
excluded due to irrelevance to 
the systematic review
2 full-text articles referenced 
by reviewed article
38 full-text articles included:
31 (82%) reviewed by 2 reviewers (MB and AL)
7 (18%) reviewed by 1 reviewer for language
39 full-text articles excluded:
25 (63%) no data on TB patients
10 (27%) no quantitative, patient-
reported HRQOL data
3 (7%) language restrictions
1 (3%) case report
28 unique cohorts described in results 
6,028 patients
5 (18%) unique cohorts included in a 
meta-analysis of HRQOL measures
Reason data not meta-analyzed:
5 (22%) cohorts did not evaluate subjects 
treated for active TB
11 (48%) did not concurrently evaluate a 
comparison group or evaluated a unique 
comparison group that could not be meta-
analyzed with another study
4 (17%) did not specify timing of evaluation 
with respect to TB diagnosis and/or treatment 
3 (13%) was the only study in a given time 
period of HRQOL administration to meet the 
meta-analysis criteria questionnaire
3 SF – 36 1 VAS 1 SGRQ 
2 (7%) unique cohorts included in the 
meta-analysis of health utilities
1 WHOQOL-BREF 2 Standard Gamble 1 EQ-5D 1 SF-6D
Fig. 1 Sampling and selection of published literature on HRQOL
among tuberculosis patients from January 1, 1960–April 1, 2011. SF-36
is short form-36, VAS is visual analog scale; SGRQ is St. George’s
respiratory questionnaire; WHOQOL-BREF is the World Health Orga-
nization’s Quality of Life BREF; EQ-5D is the EuroQoL 5D; SF-6D is the
6-dimension health utility scores derived from 11 items of the SF-36
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the SF-36; 8 of the 28 unique cohorts reported HRQOL
measures from the SF-36 [3, 4, 17, 21, 29, 33, 35, 52, 53].
Most studies used only one instrument, but three studies
used as many as four tools [16, 17, 29, 40]. Of those studies
reporting the method of assessment, 11 used only inter-
viewer-administered questionnaires, 9 studies used only
Table 1 Total sample and sub-group characteristics among subjects of reviewed studies at the time of subjects’ initial HRQOL evaluation [1–4,
6, 9, 10, 12–15, 18–21, 26, 29, 31–33, 35, 37, 38, 40, 41, 46, 47, 50, 52–54, 57, 58, 60, 61]
Subject Group Characteristics Studies
reporting
Number of subjects with available




All subjects (N = 6,028) 36 articles,
28 unique cohorts of TB patients
Demographics
Women 27 5805 (96) 2408 (42)
Mean age—years 13 2001 (33) 42




3 368 (6) 3–7
Racial/ethnic minority 6 991 (16) 517 (52)
Socioeconomic
Completed B primary
school % per study
14 3820 (63) 8–89
Unemployed % per
study
9 2316 (39) 7–80
Co-infection status and health behaviors
HIV co-infection 10 2360 (39) 696 (29)
Smokers 9 1602 (27) 597 (37)
Alcohol abuse 5 916 (15) 444 (48)
Injection drug use 2 368 (6) 19 (5)
Active TB (n = 3,541, 59 %), 24
unique cohorts
Demographics
Women 23 3524 (99) 1360 (39)
Mean age—years 18 2233 (63) 40
Foreign-born 5 416 (12) 324 (78)
Median duration in
study country—years
2 122 (3) 3–7
Racial/ethnic minority – – –
Socioeconomic
Completed B primary
school % per study
12 2410 (68) 9–76
Unemployed % per
study
9 1749 (49) 7–80
Co-infection status and health behaviors
HIV co-infection 8 722 (20) 213 (30)
LTBI (n = 639, 11 %), 6 unique
cohorts
Demographics
Women 5 614 (96) 308 (48)
Mean age—years 5 614 (96) 39
Foreign-born 3 299 (47) 260 (41)
Co-infection status and health behaviors
HIV co-infection 5 561 (88) 16 (3)
Controls (n = 1049, 17 %), 8 unique
cohorts
Demographics
Women 5 611 (58) 251 (24)
Mean age—years 5 611 (58) 38
Socioeconomic
Completed B primary
school % per study
4 383 (37) 7–26
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self-administered questionnaires, and 5 used both [1–4, 6,
9, 10, 12, 15–19, 21, 26, 31, 33, 35, 37, 38, 40, 41, 46, 47,
50, 52, 53, 57, 58, 60, 61]. One study permitted proxy
respondents [60]. Twenty-one of the 28 studies that eval-
uated subjects treated for active TB stated that the
administered HRQOL instrument was previously validated
or that their research was the validation study for this tool
[2–4, 6, 9–19, 21, 26, 29, 31, 33, 35, 37, 38, 40, 41, 46, 47,
50, 52–54, 57, 58]. Four of these studies explicitly
described ceiling effects, and three explicitly addressed
floor effects (Table 2) [4, 16–27, 38].
Assessment of data quality
The mean quality rating score was 7.3, with scores ranging
from 2.0 to 13.0. The mode was 8.0. (The greater the study
rating score, the better the perceived quality). Four of the
28 unique cohorts reported a process to check for ques-
tionnaire comprehension [4, 16, 17, 35, 46, 47]. However,
only one reported the numbers of subjects removed
because of poor comprehension [16, 17]. Twelve reported
the number of subjects who met the investigators’ inclusion
criteria [9, 10, 16, 17, 19, 21, 26, 32, 33, 35, 37, 38, 40, 41,
46, 47, 54]. The proportion of potential subjects who
refused participation ranged from 0 to 37 %, while the
Table 2 Discrimination of HRQOL instruments at initial evaluation
by patient groups, among 24 unique studies evaluating persons with
active TB [4, 16–27, 38]









Number of studies reporting 3 2 1
Range of proportion of subjects
reporting maximum score per study
5.4–53 0–25 7.2
Floor effects
Number of studies reporting 2 2 1
Range of proportion of subjects
reporting minimum score per study
0-4.0 0–2.9 0
Table 3 Quality rating scores
of articles comprising the 28
unique cohorts evaluating
HRQOL among patients with
active TB
The eight items in the quality
rating tool were extracted from
the STROBE Statement—
checklist of items that should be
included in observational
studies (version 4) based on
study characteristics anticipated
to vary widely across studies,
with particular focus on
methods and results [49]
Item 1: description of study
population
Item 2: description of sampling
mechanism
Item 3: accounting for losses to
follow-up
Item 4: quality check of HRQoL
responses performed during
data collection
Item 5: description of HRQoL
instruments used in data
collection
Item 6: data entry check before
analysis
Item 7: interviewer training
(before and throughout data
collection process)
Item 8: discussion of strengths
and limitations of study
Study [Reference] 1 2 3 4 5 6 7 8 Summary score
Aghanwa [1] 2 2 0 0 2 0 1 1 8
Aydin [2] 2 1 0 0 2 0 0 1 6
Babikako [3] 2 1 0 0 2 2 0 2 9
Bauer [4] 2 2 1 2 2 0 2 2 13
Bhatia [6], Dellborg [9, 10], Engstrom [19], Olofson [37] 1 0 0 0 1 0 0 0 2
1 2 2 0 2 0 0 1 8
Deribew [12] 2 2 2 0 2 0 1 2 11
Dhingra [13, 14] 1 2 1 0 2 0 0 1 7
Dhuria [15] 2 0 1 0 2 0 0 2 7
Dion [16, 17] 2 2 2 0 2 0 0 2 10
Fu [20] 2 0 0 0 0 0 0 0 2
Guo [21] 2 1 2 0 2 0 0 1 8
Husain [26] 1 1 1 0 2 0 1 2 8
Kruijshaar [29] 2 2 2 0 2 0 1 2 11
Lopez-Campos [31] 1 0 0 0 2 0 0 1 4
Maguire [32] 2 0 2 0 1 0 0 2 7
Marra [33] 0 2 2 0 2 0 2 1 9
Muniyandi [35] 1 0 2 2 2 2 2 2 13
Pasipanodya [38] 0 2 2 0 2 2 0 1 9
Pehrsson [40] 1 0 2 0 1 0 0 1 5
Rajeswari [41] 2 1 2 0 2 2 0 1 10
Unalan [46, 47] 2 0 2 2 2 2 0 1 11
Vinaccia [50] 1 0 0 0 2 0 0 1 4
Westaway [54] 1 2 2 0 2 0 2 1 10
Windisch [57, 58] 2 2 1 0 1 0 0 2 8
Yang [60] 2 0 0 0 0 0 0 0 2
Yelken [61] 1 0 1 0 1 0 0 0 3
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proportion of subjects who were lost to follow-up ranged
from 0 to 8 % (Table 3).
Meta-analyses
Separate meta-analyses were performed for HRQOL mea-
sures and health utility measures. Data from three unique
cohorts, using two unique instruments, contributed to the
meta-analysis of standardized mean differences in HRQOL
between subjects treated for active TB and subjects treated
for LTBI within 2 weeks of TB diagnosis [4, 16, 17, 33].
The random effect pooled estimate for the standardized
mean difference was -0.66 (95 % CI -0.82, -0.50), and
the I2 statistic was 17 % (0, 76 %). We then repeated the
meta-analysis, excluding the unpublished data of Bauer
et al. The random effect pooled estimate for the standard-
ized mean difference in HRQOL scores was -0.58 (95 %
CI -0.75, -0.40), and the I2 statistic was 0 % (0, 79 %).
Data from two cohorts, using two instruments, contributed
to the meta-analysis of standardized mean differences in
HRQOL between subjects treated for active TB and sub-
jects treated for LTBI after completing 6–8 months of
treatment [33, 38]. The random effects estimate for the
standardized mean difference was -0.51 (-0.77, -0.26),
and the I2 statistic was 54 % (0, 87 %) (Fig. 2).
Two cohorts (one unpublished), using two instruments,
met our meta-analysis criteria and evaluated subjects
treated for active TB compared to healthy controls within
2 weeks of TB diagnosis [4, 15]. The random effects
pooled estimate of the standardized mean differences in
HRQOL of these two patients groups was -1.14 (-1.75, -
0.54), and the I2 statistic was 0 % (0, 85 %). In both
cohorts, the standardized mean differences indicated lower
mean HRQOL scores reported by subjects with active TB
disease than by healthy control participants. Findings were
more similar for standardized mean differences in SF-36
PCS scores (-1.22, 95 % CI -1.58, -0.85; Bauer et al.
[4]) and WHOQOL-BREF scores (-1.62, 95 % CI -1.96,
-1.28; Dhuria et al. [15]) than for SF-36 MCS scores (-
0.58, 95 % CI -0.93, -0.24; Bauer et al. [4]).
Two cohorts (one unpublished), using two instruments,
contributed to the meta-analysis of standardized mean dif-
ferences in health utilities reported by subjects treated for
active TB and subjects treated for LTBI, within 2 weeks of
their TB diagnosis [4, 16, 17]. The random effects pooled
estimate of the standardized mean differences in health
utilities of these two patients groups was -0.62 (-0.82, -
0.42), and the I2 statistic was 89 % (69, 96 %). The stan-
dardized mean differences in Standard Gamble scores (-
0.65, 95 % CI -0.96, -0.33) and in SF-6D scores (-0.76,
95 % CI -1.08, -0.44) in the unpublished cohort of Bauer
et al. [4] suggested a greater decrement in health utility than
previously reported by Dion et al. In the latter study, the
standardized mean differences were -0.19 (95 % CI -
Fig. 2 Standardized mean differences between groups of subjects treated for active TB compared to groups of subjects treated for latent TB
infection, stratified by timing of HRQOL evaluation with respect to TB diagnosis and treatment
Qual Life Res (2013) 22:2213–2235 2219
123
0.82, 0.45) for Standard Gamble scores [16] and -0.42
(95 % CI -1.06, 0.21) for EQ-5D scores [17].
Further details about HRQOL and health utility scores in
these studies are presented in ‘‘Appendix 2’’ and Table 6 in
Appendix.
Meaningful changes in longitudinal HRQOL measures
Five of the 7 unique cohorts using a longitudinal design
reported mean HRQOL scores from subjects treated for
active TB at atleast two time points; one of these five cohorts
also reported longitudinal HRQOL scores for subjects trea-
ted for LTBI [13–15, 29, 32, 33]. Table 4 displays the cal-
culated effect sizes, comparing later with initial values.
Additional information is presented in ‘‘Appendix 3’’.
The greatest improvement in HRQOL occurred during the
first 2–3 months of treatment, among studies that evaluated
HRQOL among subjects treated for active TB at the beginning
of treatment, after the initial phase of treatment, and at/near the
end of treatment [13–15, 32]. Based on the effect sizes, instru-
ments assessing mental well-being also indicated meaningful
improvements in HRQOL after 2 months of treatment [29].
Among subjects treated for LTBI, longitudinal mea-
surements of HRQOL did not suggest meaningful changes
between diagnosis and 6 months of treatment [33].
Discussion
Subjects with active TB consistently reported poorer HRQOL
than subjects treated for LTBI and untreated controls, across a
variety of questionnaires and settings. For example, random
effects estimates of pooled standardized mean differences
demonstrated that subjects treated for active TB had mean
scores 0.66 and 0.51 standard deviations below those treated
for LTBI within 2 weeks of diagnosis and after 6–8 months of
treatment, respectively. Pooled estimates of standardized
mean differences in health utilities among subjects treated for
active TB compared to those treated for LTBI within the first
2 weeks of treatment showed similar results. The difference
between subjects treated for active TB and healthy controls
was even more pronounced. Other studies of HRQOL and
health utility measures identified by our systematic review,
but which could not be meta-analyzed, also reported a con-
sistently detrimental effect of active TB.
Based on our effect size analysis, we saw a meaningful
improvement in HRQOL throughout treatment of active
TB, and particularly during the initial, intensive phase.
Health care providers encounter detrimental effects of
TB on HRQOL particularly in their patients with active TB
disease, but to a lesser degree among those treated for
LTBI. Indeed, one study documented poorer HRQOL
Table 4 Effect sizes for longitudinal changes in HRQOL measures reported by subjects treated for active TB
























Kruijshaar [29] SF-36—PCS TB diagnosis 2 months
treatment
– – 0.23 –
Kruijshaar [29] SF-36—MCS TB diagnosis 2 months
treatment
– – 0.72b –
Kruijshaar [29] STAI-6 TB diagnosis 2 months
treatment
– – 0.24 –
Kruijshaar [29] CES-D TB diagnosis 2 months
treatment
– – 0.72b –
Maguire [32] Modified
SGRQ





Marra [33] SF-36, PCS TB diagnosis – 6 months
treatment
0.06 – –
Marra [33] SF-36, MCS TB diagnosis – 6 months
treatment
0.19 – –
Marra [33] BDI TB diagnosis – 6 months
treatment
0.31 – –
a WHOQOL-BREF is the World Health Organization’s Quality of Life BREF. SF-36 PCS and MCs are the physical and mental component
scores of the Short-Form 36 questionnaire, respectively. STAI-6 is the State-Trait Anxiety Inventory Short Form. CES-D is the Center for
Epidemiologic Studies Depression Scale. Modified SGRQ is a modified version of the St. George’s Respiratory Questionnaire. BDI is the Beck
Depression Inventory
b Meaningful change in HRQOL scores as defined by Cohen’s criteria [8, 44]
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SF-36 Health Survey (SF-36) 8 36 items measuring 8 health domains (physical functioning, role limitations due to
physical health problems, bodily pain, general health, vitality, social functioning,
role limitations due to emotional problems, mental health). Scores range from 0
to 100 with greater scores indicating better HRQOL
General Health Questionnaire 12 (GHQ
12)
4 Modified from the General Health Questionnaire 60 and contains 12 items, each
ranked on a 4-point Likert scale ranging from 0 = ‘absent’ to 3 = ‘present.’
Higher total scores indicate worse HRQOL
Beck Depression Inventory (BDI) 2 21-item in multiple choice format measuring the presence and degree of
depression among adolescents and adults. Numerical values of 0, 1, 2, or 3 are
assigned to each statement to indicate degree of severity. Items are summed to
produce an overall score—a cut-off score of C13 indicates depression, with
greater scores indicating more severe depression
Euro-QoL (EQ 5D) 2 5 domains (mobility, self-care, usual activities, pain/discomfort and anxiety/
depression). Each item is ranked on a 3-point scale ranging from ‘no problems’
to extreme problems’ with higher scores indicating better HRQOL
Hospital Anxiety and Depression Scale
(HAD)
2 14 items comprising 2 dimensions—anxiety and depression. Scores for each item
ranges from 0 to 3, with higher scores indicating worse HRQOL (i.e. more
anxiety and depression)
Mood Adjective Check List Short Form
(MACL)
2 38 items categorized into 3 dimensions (pleasantness, activation, calmness).




2 49 items comprising 7 domains (respiratory complaints, physical functioning,
attendant symptoms and sleep, social relationships, anxiety, psychological well-
being, social functioning). Items are rated on a 5-point Likert scale from
‘strongly disagree’ to ‘strongly disagree’. Higher scores indicate better HRQOL
SF-6D utility score 2 11-item generic preference-based single index measure of health status. Scores
range from 0 to 1.0, with higher scores indicating better HRQOL
Sickness Impact Profile (SIP) 2 136 items measuring 12 domains (sleep and rest, emotional behavior, body care
and movement, home management, mobility, social interaction, ambulation,
alertness, behavior, communication, work, recreation and pastimes, eating).
Subjects endorse items that describe themselves. Scores are calculated as a
percentage of total dysfunction; a cut-off score[10 indicates severe dysfunction
Standard Gamble 2 Subject choose between certainty of remaining in a given health state and a
hypothetical gamble, between the possible outcomes of perfect health and death.
Probability of having perfect health in the gamble is lowered from 100% until the
subject is indifferent between the choices. (Administration assisted with the use
of a colored probability wheel.) The midpoint of the values between this
probability of perfect health and the previous probability is the HRQOL score.
Scores range from 0 to 1, with higher scores indicating better HRQOL
State-Trait Anxiety Inventory Short Form
(STAI-6)
2 6 items are rated on a 4-point scale. (Created from the 40-item Spielberger State-
Trait Anxiety Inventory.) Items are scaled using a 4-point Likert scale indicating
levels of anxiety with 1 = ‘not at all’ to 4 = ‘very much.’ Total scores range from
20 to 80 with a cut-off total score [44 demonstrating that the subject is highly
anxious. (Higher scores indicate worse HRQOL)
Visual Analog Scale (VAS) 2 Two methods used: (1) 10-cm scale with 0 cm = ‘death’ and 10 cm = ‘perfect
health’ and (2) 100-cm ‘feeling thermometer’ with 0 cm = ‘death’ and 100 cm =
‘perfect health’. Patients are asked to mark on these scales where they rate their
own state of health. Higher scores indicate better HRQOL
Beck Depression Inventory (BDI Short
Form)
1 13 items in multiple choice format measuring the presence and degree of
depression among adolescents and adults. Numerical values of 0, 1, 2, or 3 are
assigned to each statement to indicate degree of severity. Items are summed to
produce an overall score with cut-offs of 0-3 = none or minimal depression, 4–7
= mild depression, 8–15 = moderate depression, and C16 = severe depression.
(Higher scores indicate worse HRQOL)
Brief Disability Questionnaire (BDQ) 1 11 items scored on a scale from 0 = never to 2 = always or severe; higher scores
indicate worse HRQOL






Center for Epidemiologic Studies
Depression Scale (CES-D)
1 15 items each ranked on a 4-point Likert scale ranging from ‘not at all’ to ‘very
much’. Total scores range from 0 to 60, with a score cut-off C16 suggesting a
clinically significant level of depressive symptoms. (Higher scores indicate
worse HRQOL)
DR-12 1 12 items comprising 2 domains—symptoms and socio-psychological & exercise
adaptation. Each item is ranked on a scale from 1 to 3; higher scores indicate
better HRQOL
Duke Health Profile (DUKE) 1 63 items comprising 4 dimensions (symptom status, physical function, social
function, and emotional function). Scores are generated for each domain is
scored on a scale of 0–1; higher scores indicate better HRQOL
Dysfunctional Analysis Questionnaire
(DAQ)
1 50 items comprising 5 domains (social, vocational, personal, familial, cognitive).
Each item rated on a 5-point Likert scale with 1 = better functioning than that
before onset of illness and 5 = severe impairment compared to before illness
onset; higher scores indicate worse HRQOL
Health Utilities Index 2 (HUI 2) 1 7 items (sensation, mobility, emotion, cognition, self-care, pain, fertility) each with
3 to 5 levels. Utility functions are assigned to each level of each item from which
that total health utility is calculated that ranges from 0 (death) to 1 (perfect
health)
Health Utilities Index 3 (HUI 3) 1 8 items (vision, hearing, speech, ambulation, dexterity, emotion, cognition, pain)
each with 5 to 6 levels. Utility functions are assigned to each level of each item
from which that total health utility is calculated that ranges from 0 (death) to 1
(perfect health).
Kessler 10 1 10 items each ranked on a 5-point Likert scale ranging from 1 = ‘never’ to 5 = ‘all
of the time’. Higher scores indicate better HRQOL
Life Satisfaction Index Z 1 A short form version of the Life Satisfaction Index A containing 13 items. Subjects
are asked to agree or disagree with the statement. Total scores range from 0 to
26, with higher scores indicating greater HRQOL
Modified version of SF-36 1 14 items among 3 domains (physical well-being, mental well-being, and social
well-being). Responses are categorized into 1 of 3 categories: ‘‘worse,’’ ‘‘same as
before,’’ and ‘‘better’’. Total scores range from 0 to 100; higher scores indicate
better HRQOL
Modified version of St. George’s
Respiratory Questionnaire (SGRQ)
1 A version of the SGRQ suited to the study population, located in the Timika
District, Papua Province, Indonesia. For more details refer to the SGRQ below
Present State Examination (PSE) 1 A combination of the 30-item General Health Questionnaire and a Self-rating
Depression Scale. The 30-item General Health Questionnaire is a modified
version of the General Health Questionnaire 60 and contains 30 items, each
ranked on a 4-point Likert scale ranging from 0 = ‘absent’ to 3 = ‘present.’
Higher total scores indicate worse HRQOL. The Self-rating Depression Scale is
designed to assess the level of depression among individuals diagnosed with a
depressive disorder. There are 20 items comprising 4 domains (the pervasive
effect, the physiological equivalents, other disturbances, and psychomotor
activities). Each item is ranked on a scale of 1 = ‘a little of the time’ to 4 = ‘most
of the time’. Higher scores indicate worse HRQOL with cut-off scores of 20-49 =
normal range, 50–59 = mildly depressed, 60–69 = moderately depressed, C70 =
severely depressed
Rosenberg Self-Esteem Scale (RSE) 1 10 items with each item ranked on a 4-point Likert scale from ‘strongly agree’ to
‘strongly disagree’; higher scores indicate better HRQOL
Self-Rating Anxiety Scale (SAS) 1 20 items each ranked on 4-point, Likert scale where 1 = ‘a little of the time’ and 4
= ‘‘most of the time. Total scores range from 20–80 with score classifications:
20–44 points = normal range anxiety; 45–59 points = mild to moderate anxiety
levels; 60–74 points = marked to severe anxiety levels; 75–80 extreme anxiety
levels. Higher scores indicate worse HRQOL
Sheehan Disability Scale (SDS) 1 20 items comprising 3 domains: work, family, and social lives. Each item rated by
using a 10-point visual analog scale with 0 = ‘unimpaired’ to 10 = ‘highly
impaired.’ Total scores range from 0 to 30; higher scores indicate worse
HRQOL. Scores C5 in any of the 3 domains indicates significant impairment
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among subjects treated for latent TB, compared to healthy
controls [4]. These decrements are also highly relevant to
decision makers, in approaching tradeoffs between pro-
viding preventive treatment for a large number of persons
with LTBI, versus the smaller number who may ultimately
develop active TB [28, 30].
It is worth noting that available studies primarily reflect
the experiences of young and middle-aged, predominantly
male adults—corresponding to the profile of reported TB
cases in most countries [11]. Other socio-demographic
characteristics of subjects varied widely, although data
were sparse. Over 75 % of subjects with reported immi-
gration status were immigrants to low TB incidence
countries. Immigrants also face a unique set of chal-
lenges—adapting to new cultural norms and languages,
obtaining and sustaining paid work, and accessing health
care (for TB diagnosis/treatment and otherwise). These
may all independently and synergistically affect HRQOL.
Our results may therefore be particularly relevant to low-
incidence countries, as immigrants represent the majority
of persons screened, diagnosed, and treated for active TB
disease and LTBI in such settings.
With a comprehensive search strategy yielding 76 arti-
cles, this systematic review builds on a review published in
2009 and is the first to provide pooled estimates from
formal meta-analyses [22]. In this earlier review, subjects
with active TB were also shown to have substantial deficits
in HRQOL, compared to subjects treated for LTBI. Mental
well-being was more severely disrupted than physical
health among patients in both treatment groups. Our results
are also similar with respect to improvement during treat-
ment of active TB [22].
While 28 unique cohorts of patients with TB were
included in our systematic review, 3 potentially relevant
articles were excluded because they were published in
Russian. Hence, our estimates of HRQOL may be affected
by some selection bias. However, the main findings of our
review were consistent across a variety of settings.
Some information could be gleaned from the English
abstracts of two of these articles. Sukhov and Sukhov
found that men with chronic pulmonary TB rated their
HRQOL worse than men with their first case of pulmonary
TB [45]. Shalaeva et al. [43] reported improvements in all
sub-scales of the SF-36 among 59 adults who received
surgical treatment and chemotherapy for pulmonary TB.
This latter finding in particular supports findings of
improved HRQOL scores throughout active TB treatment
among the studies included in this review.
Only 2 studies retrieved from the search included





Social Support Rating Scale (SSRS) 1 10 items to assess the perceived helpfulness of different types of individuals to the
subject. Each item is assessed using a 3-point, Likert scale ranging from 1 = ‘not
at all helpful’ to 3 = ‘a great deal helpful’. Higher scores indicate more social
support
St. George Respiratory Questionnaire
Short Form (SGRQ)
1 A disease-specific instrument designed to assess patients with mild to severe
airway disease. 50 items comprise 3 domains (symptoms, activity, and impacts).
Scores are scaled from 0 to 100, with better scores indicating worse HRQOL
Symptoms Check List (SCL-90) 1 90 items comprising 9 domains (somatization, obsessive-compulsive, interpersonal
sensitivity, depression, anxiety, anger-hostility, phobic anxiety, paranoid
ideation, psychoticism). Three global indices (Global Severity Index, Positive
Symptom Total, and Positive Symptom Distress Index) can also be calculated.
Each item is ranked on a 5-point Likert scale, ranging from 0 = ‘not at all’ to 4 =
‘extremely’; higher scores indicating worse HRQOL
Voice Handicap Index-10 (VHI-10) 1 Assessment specific to voice handicap. 30 items comprising 3 domains (functional,
physical, and emotional aspects of voice disorders). Each item is ranked on a
5-point Likert scale with 0 = never to 4 = always; higher scores indicate worse
HRQOL
World Health Organization’s Quality of
Life—BREF (WHOQOL-BREF)
1 Based on the WHOQOL-100. 26 items across 5 domains (physical health,
psychological health, social relationships, environment) are ranked on a 5-point
Likert scale ranging from 1 = ‘not at all’ to 5 = ‘an extreme amount’. Higher
scores indicate better HRQOL
World Health Organization’s Quality of
Life—HIV (WHOQOL-HIV)
1 Based on the WHOQOL-100 questionnaire, to be used for patients with HIV/
AIDS. 115 items (comprising 30 facets) are each ranked on a 5-point Likert scale
ranging from 1 = ‘not at all’ to 5 = ‘an extreme amount’. Higher scores indicate
better HRQOL
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Country Time of assessment and associated
measures
Patient groups






2007–2008 Uganda Within 2 weeks of TB diagnosis, N 23 0 0 20 TB/HIV co-
infected patients
Mean PCS (95 % CI) 61 (52,70) – – 55 (NA)
Mean MCS (95 % CI) 61 (53,69) – – 59 (NA)
One to two months of TB treatment, N 19 0 0 20 TB/HIV co-
infected patients
Mean PCS (95 % CI) 70 (61, 79) – – 64 (NA)
Mean MCS (95 % CI) 72 (65,79) – – 67 (NA)
6–8 months of TB treatment, N 23 0 0 20 TB/HIV co-
infected patients
Mean PCS (95 % CI) 65 (55, 75) – – 77 (NA)
Mean MCS (95 % CI) 68 (59, 77) – – 80 (NA)
Bauer et al.
[4]
2008–2011 Canada Within 2 weeks of TB diagnosis, N 61 119 77 0
Mean PCS (95 % CI) 49 (47, 51) 56 (55,
57)
57 (56, 58) –
Mean MCS (95 % CI) 44 (41, 47) 50 (49,
51)
50 (48, 52) –
Dion et al.
[17]
1999–2000 Canada Within 2 weeks of TB diagnosis, N 17 25 0 8 patients 6 months
post-TB treatment
completion
Mean PCS (95 % CI) 53 (49, 57) 58 (56,
60)
– 56 (40, 72)
Mean MCS (95 % CI) 49 (47, 57) 57 (53,
62)
– 49 (23, 74)
Guo et al.
[21]
2008a Canada One to two months of TB treatment, N 84 78 0 0
Mean PCS (95 % CI) 45 (42, 48) 55 (53,
56)
– –





2008 England Within 2 weeks of TB diagnosis, N 42 0 0 0
Mean PCS (95 % CI) 36 (32, 40) – – –
Mean MCS (95 % CI) 42 (38, 45) – – –
One to two months of TB treatment, N 31 0 0 0
Mean PCS (95 % CI) 39 (35, 43) – – –
Mean MCS (95 % CI) 50 (46, 53) – – –
Marra et al.
[33]
2005–2006 Canada Within 2 weeks of TB diagnosis, N 104 102 0 0
Mean PCS (95 % CI) 48 (45, 50) 55 (52,
57)
– –
Mean MCS (95 % CI) 43 (40, 45) 52 (49,
54)
– –
Six to eight months of TB treatment, N 70 75 0 0
Mean PCS (95 % CI) 49 (46, 51) 54 (53,
56)
– –





1996 China One to two months of TB treatment, N 228 0 228 0
Mean PCS (95 % CI) 65 (61, 68) – 84 (81, 87) –
Mean MCS (95 % CI) 61 (58, 64) – 74 (72, 76) –
GHQ-12









Country Time of assessment and associated
measures
Patient groups





1995–1996 Nigeria Unspecified time during TB treatment, N 53 0 20 20 long-stay
orthopedic
patients





1999 Turkey Unspecified time during TB treatment,
hospitalized (new/default/MDR), N
42/38/39 0 0 38 COPD patients










Unspecified time during TB treatment,
hospitalized, N
100 0 0 0
Mean total score (95 % CI) 13.6 (11.9, 15.2) – – –
Unalan et al.
[46, 47]
2003–2004 Turkey Unspecified time during TB treatment, N 196 108 196 0









1999–2000 Canada Within 2 weeks of TB diagnosis, N 17 25 0 8 subjects 6 months
post-TB treatment
completion
Mean total score (95 % CI) 79 (68, 90) 88 (81,
95)
– 88 (62, 100)
Kruijshaar
et al. [29]
2008 England Within 2 weeks of TB diagnosis, N 61 0 0 0
Mean total score (95 % CI) 67 (66, 68) – – –
One to two months of TB treatment, N 55 0 0 0




2008a Pakistan Unspecified time during TB treatment, N 108 0 0 0
N (%) classified with anxiety (HAD score
C11)
51 (47) – – –
n (%) classified with depression (HAD
score [ 11)




2008–2011 Canada Within 2 weeks of TB diagnosis, N 61 119 77 0








2008a Canada One to two months of TB treatment, N 84 78 0 0







2008–2011 Canada Within 2 weeks of TB diagnosis, N 61 119 77 0







1999–2000 Canada Within 2 weeks of TB diagnosis, N 17 25 0 8 subjects 6 months
post-TB treatment
completion
Mean total score (95 % CI) 0.9 (0.8, 0.9) 0.9
(0.80,
1.0)
– 1.0 (0.90, 1.0)
STAI-6









Country Time of assessment and associated
measures
Patient groups





2008 England At TB diagnosis, N 61 0 0 0
Mean total score (95 % CI) 57 (44, 53) – – –
One to two months of TB treatment. N 55 0 0 0
Mean total score (95 % CI) 47 (40, 48) – – –
Unalan et al.
[46, 47]
2003–2004 Turkey Unspecified time during TB treatment, N 196 108 196 0









1999–2000 Canada Within 2 weeks of TB diagnosis, N 17 25 0 8 subjects 6 months
post-TB treatment
completion
Mean total score (95 % CI) 78 (49, 100) 89 (71,
100)
– 88 (68, 100)
Guo et al.
[21]
2008a Canada One to two months of TB treatment, N 84 78 0 0








Unspecified time during TB treatment,
hospitalized, N
100 0 0 0




1999 Turkey Unspecified time during TB treatment,
hospitalized (new/default/MDR), N
42/38/39 0 0 38 COPD patients








2008 England At TB diagnosis, N 61 0 0 0
Mean total score (95 % CI) 22 (18, 25) – – –
One to two months of TB treatment, N 61 0 0 0





2002 India Beginning of TB treatment, N 43 0 0 0
Mean total score (95 % CI) 25.6 (24.3, 26.9) – – –
Completion of initial phase TB treatment,
N
43 0 0 0
Mean total score (95 % CI) 33.1 (32.3, 33.9) – – –
At TB treatment completion, N 43 0 0 0




2007a Colombia Unspecified time during TB treatment, N 60 0 0 0




2001a India Unspecified time during TB treatment, N 50 0 0 0




2008a Canada One to two months of TB treatment, N 84 78 0 0














Country Time of assessment and associated
measures
Patient groups





2008a Canada One to two months of TB treatment, N 84 78 0 0







2009 Ethiopia Within the initial phase TB treatment,
hospitalized & HIV co-infected with
75 % subjects on ART, N
467 0 0 155 HIV-only
patients on ART
n (%) depressed among those in good
physical health
7 (37) – – 59 (27)
n (%) depressed among those in poor
physical health
12 (63) – – 159 (73)
Life Satisfaction Index Z
Fu et al. [20] 2001–2004 China Unspecified time during TB treatment, N 510 0 100 0






2001 India At TB diagnosis. N 610 0 0 0






After initial intensive phase TB treatment.
N
610 0 0 0






At TB treatment completion. N 610 0 0 0









2003–2004 Indonesia At TB diagnosis, N 115 0 0 0
Mean total score (95 % CI) 44.6 (40.2, 48.9) – – –
One to two months of TB treatment, N 65 0 0 0
Mean total score (95 % CI) 19 (17.0, 21.0) – – –
Six to eight months of TB treatment, N 66 0 0 0




1995–1996 Nigeria Unspecified time during TB treatment, N 53 0 20 20 long-stay
orthopedic
patients
n (%) of patients with a psychiatric
disorder






Unspecified time during TB treatment,
hospitalized, N
100 0 0 0
Mean total score (95 % CI) 28.0 (26.8, 29.2) – – –
SAS
Fu et al. [20] 2001–2004 China Unspecified time during TB treatment, N 510 0 100 0
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Additionally, only 1 study included in this review evalu-
ated subjects with multi-drug resistant TB (MDR-TB), and
no studies evaluated children less than 11 years of age.
Hence, our systematic review could not adequately address
HRQOL among these groups, whose experience may differ
substantially from that of other TB patients.
This systematic review synthesized the information
from studies of quantitative evaluations of HRQOL; we did
not review the body of research using qualitative methods
to address HRQOL as it was beyond the scope of our study
objectives. However, qualitative studies can offer health
care providers valuable insight regarding patients’ experi-
ences and needs in specific settings and should be used to
supplement the quantitative information provided in this
review.
The conclusions drawn from a systematic review depend
on the quality of the individual studies included. One major
limitation of the studies is that very few adequately mea-
sured and described key social and behavioral determinants








Country Time of assessment and associated
measures
Patient groups
Active TB LTBI Healthy
Controls
Other
Fu et al. [20] 2001–2004 China Unspecified time during TB treatment, N 510 0 100 0






2003 China Unspecified time during TB treatment,
hospitalized, N
132 0 71 0




2005–2006 USA Six to eight months of TB treatment, N 105 199 0 0






2003 China Unspecified time during TB treatment,
hospitalized, N
132 0 71 0




2008a Turkey At start of TB treatment, N 14 0 0 0
Median score (range) 24 (22–24) – – –
Six to eight months of TB treatment, N 14 0 0 0




2004–2005 India At start of TB treatment, N 90 0 90 0
Mean total score (95 % CI) 11.8 (11.5, 12.0) – 14.2 (14.0,
14.4)
–
Three months of TB treatment, N 90 0 Not
available
0
Mean total score (95 % CI) 13.2 (13.0, 13.5) – – –
At treatment completion, N 90 0 Not
available
0




2009 Ethiopia Within the initial phase TB treatment,
hospitalized & HIV co-infected, N with
75 % subjects on ART
467 0 0 155 HIV-only
patients on ART
Range mean domain scores 12.4–17.9 – – 11.6–16.5
CI confidence interval, NA data not available
a Date reflects publication date; data collection data not available
b New = new case of active TB for that patient; default = defaulted from previous TB treatment regimen; MDR = multidrug resistant TB
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to crude pooled estimates of HRQOL. We did not have
sufficient information to permit meta-regression, which
could help account for important confounders (e.g., foreign
birth, substance use, co-morbidities) when comparing
persons with active TB to those treated for LTBI and
healthy control subjects.
Most studies were cross-sectional, and none reported
measurements from a randomized clinical trial. Longitu-
dinal observational studies can provide valuable insight
into changes in HRQOL as patients undergo different
phases of treatment, particularly for active TB. A longitu-
dinal design, where subjects with active and LTBI are
compared to suitable controls, will be particularly useful in
this respect.
Inaccurate measures of HRQOL were possible as only 3
of the 28 cohorts included a process for checking ques-
tionnaire comprehension, and only one indicated the
number of subjects excluded accordingly. Persons so
excluded may have more limited educational attainment or
language skills, which may make study samples less rep-
resentative of the TB patient population, and perhaps lead
to overestimation of HRQOL because of this exclusion.
Additionally, one study contributing data to meta-analyses
was not yet peer-reviewed [4]. Sensitivity analyses with
removal of these data were performed accordingly, with
generally similar findings.
Refusals ranged from 0 to 37 % in the 12 studies that
provided this information. It is possible that subjects who
refused to participate had more severe TB disease and/or a
higher prevalence of risk behaviors, though this could not
be assessed directly. These refusals could also make study
samples less representative and potentially bias our results.
Similarly, certain eligibility criteria might limit the repre-
sentativeness of some studies.
Finally, most included studies appeared to be of mod-
erate quality, with the most frequent quality score being 8
Table 7 Mean HRQOL scores reported by studies by studies evaluating HRQOL among subjects with post-TB sequelae using home mechanical
ventilation (HMV) and other comparison patient groups also on HMV






Dellborg et al. [9, 10, 19, 37] 1992–1995 Sweden n (%) 17 (44) 22 (56)
Mean total score (95 % CI) 3.5 4.9
Pehrsson et al. [40] 1994a Sweden n (%) 5 (13) 34 (87)
Mean total score 4.4 5.1
HAD
Pehrsson et al. [40] 1994a Sweden n (%) 5 (13) 34 (87)
Mean anxiety score 2.3 2.8
Mean depression score 4 1.8
MACL
Dellborg et al. [9, 10, 19, 37] 1992–1995 Sweden n (%) 17 (44) 22 (56)
Mean total score 2.7 3.3
Pehrsson et al. [40] 1994a Sweden n (%) 5 (13) 34 (87)
Range of domain mean scores 3.4–3.6 3.4–3.4
SIP
Dellborg et al. [9, 10, 19, 37] 1992–1995 Sweden n (%) 17 (44) 22 (56)
Mean total score 15 8.3
Pehrsson et al. [40] 1994a Sweden n (%) 5 (13) 34 (87)
Mean total score 4.4 5.1
SRI
Lopez-Campos et al. [31] 2004–2006 Spain n (%) 12 (10) 103 (90)
Mean total score 59 58
Windisch et al. [57, 58] 2003a Germany n (%) 20 (9) 206 (91)
Mean total score 52 56
CI confidence interval
a Date reflects publication date; data collection data not available
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out of a possible 16 points. Although this rating system was
not formally validated, it may highlight gaps in reporting
parameters that are relevant to the assessment of HRQOL
in the TB patient population.
Conclusions
In a variety of studies, subjects with active TB consistently
reported poorer HRQOL than persons treated for LTBI and
untreated controls. This is important for understanding the
non-fatal outcomes of active TB and the potential benefits
of preventive interventions.
Future research on HRQOL in the TB context should
better address social and behavioral health determinants.
Further information is also needed for some of the most
vulnerable persons with TB, such as those with TB/HIV
co-infection, MDR-TB, and younger children.
In the TB context, meaningful cross-sectional differ-
ences and longitudinal changes have not been defined for
many of the measurement tools we reviewed. A longitu-
dinal study now underway compares HRQOL and health
utilities over a 12-month follow-up period, among persons
treated for active TB, LTBI, and untreated, healthy controls
of similar background. This research will help address this
gap in low-incidence settings, allow for better assessment
of the benefits and limitations of TB control interventions,
and may assist health care providers to better target phys-
ical and psychosocial support.
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Appendix 1
We used the following search strategy to retrieve relevant
articles from eight databases.
((‘‘Mycobacterium tuberculosis’’[MeSH]) OR (‘‘tuber-
culosis’’[MeSH]) OR (‘‘TB’’[title/abstract])) AND ((‘‘qual-
ity of life’’[MeSH]) OR (‘‘QoL’’[title/abstract]) OR
(‘‘quality adjusted life years’’[MeSH]) OR (‘‘QALY’’[title/
abstract]) OR (‘‘health utility*’’[title/abstract]) OR (‘‘health
status’’[MeSH]) OR (‘‘life quality*’’[title/abstract]) OR
(‘‘well-being’’[title/abstract]) OR (‘‘disability adjusted life
year*’’[title/abstract]) OR (‘‘DALY*’’[title/abstract]) OR
(‘‘treatment outcome’’[MeSH]) OR (‘‘outcome*’’[title/
abstract]) OR (‘‘outcome assessment (health care)’’[MeSH])
OR (‘‘cost and cost analysis’’[MeSH]) OR (‘‘cost of ill-
ness’’[MeSH]) OR (‘‘disability*’’[title/abstract]) OR
(‘‘health-related quality of life’’[title/abstract]) OR
(‘‘HRQOL’’[title/abstract]) OR (‘‘ql’’[title/abstract])).
Appendix 2
The following information supplements the results pub-
lished in the main manuscript relating to studies evaluating
subjects with active TB. Refer to Table 6 in Appendix.
Active TB subjects consistently reported Short Form 36
(SF-36) Physical Component Scores (PCS) and Mental
Component Scores (MCS) lower than concurrently evalu-
ated patients treated for latent TB infection (LTBI) or
healthy controls [3, 4, 17, 21, 29, 33, 35, 52, 53]. In the
longitudinal studies, active TB patients rated their HRQOL
better throughout their treatment, except for one study [3].
The previously treated subjects evaluated by Dion et al.
[17] reported better or comparable physical and mental
well-being than their active TB counterparts, but worse
physical and mental well-being compared to the concur-
rently evaluated subjects treated for LTBI. Babikako et al.
assessed HRQOL among smear-positive, pulmonary TB
patients and TB/HIV co-infected individuals; as expected,
the latter patient group reported lower PCS and MCS
compared to the former except at the last evaluation. An
additional study (Muniyandi et al. [35]) evaluated HRQOL
of 436 subjects in India between 2003 and 2004 who were
new cases of active TB, completed treatment, and were
disease- and infection-free for 1 year since the completion
of their active TB treatment regimen. Mean PCS and MCS
scores demonstrated improved physical and mental well-
being after 1 year of completing treatment compared to all
active TB scores shown in Table 6 in Appendix [35].
Two studies used the GHQ-12 to assess HRQOL among
subjects with active TB [1, 2]. Aghanwa et al. [1] examined
active TB patients, long-stay hospitalized orthopedic
patients, and healthy hospital workers in Nigeria; HRQOL
improved across these three groups, respectively. Aydin
et al. [2] assessed HRQOL in a Turkish population among
incident cases of active TB, patients with active TB who
have defaulted from previous treatment, and subjects with
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multi-drug resistant (MDR) TB. Incident active TB sub-
jects rated their HRQOL better than defaulted or MDR-TB
cases. However, a group of concurrently measured patients
with Chronic Obstructive Pulmonary Disease (COPD)
rated their HRQOL even worse than the patients with
MDR-TB. Mean scores of each of the three TB patient
groups rated their HRQOL better than the active TB sub-
jects in the study by Aghanwa et al., which may be
explained by the difference in socioeconomic status
between Turkey and Nigeria.
Two studies used the Beck Depression Inventory (BDI)
at assess HRQOL among subjects treated for active TB—
Westaway et al. evaluated patients hospitalized in South
Africa and Unalan et al. [47, 48, 54] assessed Turkish
patients treated for active TB, patients treated for LTBI,
and a healthy control group. All subjects treated for TB
reported worse HRQOL compared to the healthy controls
and met the cut-off for depression, but the South African
patients rated their HRQOL better than both treated groups
of Turkish patients.
Two studies used the EQ-5D instrument to measure
health utilities among subjects treated for active TB [17,
29]. The mean score reported by subjects evaluated by
Dion et al. [17] indicated better HRQOL compared to those
evaluated by Kruijshaar et al. In the former study, those
treated for LTBI and previously treated subjects reported
the same health utilities. These results indicate that in a
low-prevalence setting, health utilities among those treated
for active TB may improve to the level of a patient treated
with preventative treatment after 6 months of completing
therapy for active TB disease. Subjects treated for active
TB in the study by Kruijshaar et al. indicated similar
improvements in health utilities throughout treatment as
those reported with the SF-36.
When measuring HRQOL among active TB subjects in
Pakistan with the Hospital Anxiety and Depression Scale
(HAD), Husain et al. [26] found that 47 % of their subjects
met the anxiety criteria score, and 46 % of their subjects
met the depression criteria score.
Two studies calculated the SF-6D metric from data
collected with the SF-36 [4, 21]. Mean SF-6D scores among
subjects treated for active TB were about 0.10 points lower
than those treated for LTBI within 2 weeks of TB diagnosis.
Health utilities reported by healthy controls were identical
to those reported by subjects treated for LTBI [4]. Although
studied after one to 2 months of treatment, patients of the
Guo et al. study reported similar SF-6D mean scores to
those patients evaluated by Bauer et al.
Subjects treated for active TB in the study by Dion et al.
reported health utilities measured with the Standard Gam-
ble that indicated better HRQOL than those subjects treated
for active TB studied by Bauer et al. [4, 16]. Similar health
utilities were reported by concurrently studied subjects
treated for LTBI. Perfect health was reported by the heal-
thy controls in the Bauer et al. study as well as the subjects
previously treated for active TB in the Dion et al. study.
Although the sample size was limited in the Dion et al.
study, these results may indicate a return to excellent health
utility within 6 months of completing active TB treatment
in a low-prevalence setting.
Unalan et al. and Kruijshaar et al. [29, 46, 47] used the
STAI-6 to evaluate HRQOL among patients with active TB.
Unalan et al. [46, 47] found that subjects treated for active TB
reported the same HRQOL as the concurrently evaluated
subjects treated for LTBI. Similar to patterns found with the
SF-36 and the EQ-5D, subjects treated for active TB in the
study by Kruijshaar et al. [29] reported an improvement in
HRQOL with STAI-6 throughout treatment.
Two studies examined HRQOL among Canadian
patients with active TB using the VAS—Guo et al. [16, 21]
used a 10-cm ‘feeling thermometer’ with 0 cm = ‘death’
and 10 cm = ‘perfect health,’ and Dion et al. used a
100-cm scale with 0 cm = ‘death’ and 100 cm = ‘perfect
health’. In both studies, participants were asked to mark on
the scale how they rated their own health state at the time
of the interview. The mean scores of the active TB patients
evaluated by Dion et al. were 12 points greater than the
mean score reported by the subjects studied by Guo et al.
[16, 21]. Side effects from active TB treatment would not
have occurred within 2 weeks of TB diagnosis, which
likely explains the differences in the mean scores between
these 2 studies. Mean scores reported by those subjects
treated for LTBI were similar in the 2 studies and also
similar to the mean score reported by those subjects pre-
viously treated for active TB in the study by Dion et al. [16,
21]. This supports the notions that (1) even after 2 months
of LTBI treatment, subjects do not see a deficit in HRQOL,
(2) subjects treated for active TB report far worse HRQOL
than those treated for LTBI (as was seen in multiple studies
that assessed HRQOL using the SF-36), and (3) subjects
who complete active TB treatment may return to a level of
HRQOL similar to individuals treated for LTBI.
The Brief Disability Questionnaire (BDQ) was used by
Aydin et al. [2] who found a downward gradation in
HRQOL from new cases of active TB, to persons with
active TB who had defaulted from treatment, to patients
with MDR-TB. The group of subjects with COPD, how-
ever, rated their HRQOL much worse than even the group
of patients with MDR-TB. This trend was similar to that
found when using the GHQ-12 as described above.
The Center for Epidemiologic Studies Depression Scale
(CES-D) used by Kruijshaar et al. [29] indicated that the
HRQOL improved from TB diagnosis to 2 months of
completed TB treatment among active TB subjects. These
results were similar to those found with the SF-36, EQ-5D,
and STAI-6 [29].
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Dhingra et al. [14, 15] used the DR-12 to assess HRQOL
among active TB subjects at the beginning of TB treat-
ment, at the completion of the initial phase of TB treat-
ment, and at the completion of the TB treatment regimen.
Subjects reported improved HRQOL throughout the course
of TB treatment.
The multi-attribute health utility indices (HUI2 and
HUI3, score ranges from 0 to 1) were used by the Guo et al.
[21] to evaluate both active TB patients and patients treated
for LTBI. Health utilities for the active TB patients were
0.09 points lower with the HUI3 than with the HUI2. On
average, the subjects treated for LTBI reported health
utilities 0.08 points higher than active TB patients on the
HUI2 and 0.14 higher on the HUI3 [21].
Deribew et al. [12] used the Kessler 10 to compare
HRQOL among subjects with TB/HIV to HIV-positive
individuals without active TB, referred to as ‘HIV-only’
subjects. All subjects were hospitalized at HRQOL evalu-
ation. All TB/HIV subjects were within the initial phase of
TB treatment, and 75 % of these subjects were also taking
anti-retroviral therapy (ART). All HIV-only patients were
taking ART. Among the patients classified by the authors
to be in good physical health, a greater proportion of the
TB/HIV subjects were classified with depression than the
HIV-only patients [12]. These results are similar to those
reported by TB/HIV co-infected patients evaluated by
Babikako et al. with the SF-36 [29].
Two different studies conducted in China examined
HRQOL among subjects with active TB and those treated
for LTBI [20, 60]. Fu et al. [20] found that active TB
subjects rated their HRQOL worse than the patients treated
for LTBI when using the Life Satisfaction Index Z, the
SAS, or the SDS. Although Yang et al. [60] found no
difference in mean SSRS scores reported by subjects
treated for active TB and those treated for LTBI, active TB
subjects rated their HRQOL more than 10 points worse
than concurrently assessed subjects treated for LTBI when
using the SCL-90.
Rajeswari et al. [41] evaluated active TB patients in
India at 3 different time points with a modified version of
the SF-36: at TB diagnosis, after completing 2 months of
TB treatment, and after treatment completion. Table 6 in
Appendix shows a wide range of the proportion of subjects
reporting good HRQOL on physical, mental, and social
domains across the 3 evaluations [41].
Maguire et al. [32] used a modified version of the SGRQ
to evaluate subjects treated for active TB at diagnosis, and
after completing 2 and then 6 months of treatment. Similar
to other studies reported above, HRQOL reported by these
patients improved throughout the course of treatment [32].
Aghanwa et al. [1] found a greater proportion (30 %) of
subjects with active TB were classified as having a psy-
chiatric disorder when using the Present State Examination
(PSE) compared to subjects treated for LTBI (10 %) and
long-term hospitalized orthopedic patients (5 %).
After 6–8 months of TB treatment, subjects treated for
LTBI reported better HRQOL than those subjects treated
for active TB, as measured by Pasipanodya et al. [38] using
the SGRQ.
Fourteen patients with laryngeal active TB were evalu-
ated by Yelken et al. [61] with the VHI-10 questionnaire at
the start of treatment and during a follow-up visit, which
occurred within 6 weeks to 9 months of completing treat-
ment. HRQOL improved from the start of treatment to the
completion of treatment in this sample [61].
Dhuria et al. [15] used the World Health Organization’s
Quality of Life Questionnaire—BREF (WHOQOL-BREF)
to assess HRQOL among subjects with active TB in India
at the start of TB treatment, after completing 3 months of
TB treatment, and after completing the entire regimen.
Similar to numerous studies described above, mean
HRQOL scores improved from the initial evaluation
through the 2 follow-up assessments [15]. However, the
mean HRQOL scores of the active TB patients never
reached the mean scores of LTBI-treated subjects assessed
at the start of their TB treatment.
Contrary to their results found with the Kessler 10,
Deribew et al. [12] found that the range of WHOQOL-HIV
scores for the TB/HIV subjects indicated slightly better
HRQOL than the HIV-only group. However, after con-
trolling for a number of confounding variables such as age,
sex, occupation, CD4 lymphocyte count in a multivariable
model, TB/HIV subjects had lower mean scores in all
domains of the WHOQOL-HIV [12]. Significantly greater
proportion of TB/HIV subjects had lower CD4 lymphocyte
counts compared to HIV-only subjects (57.5 % compared
to 27.3 %, respectively), which may contribute to the lower
HRQOL among the former group [12].
Appendix 3
The following information supplements the results pre-
sented in Table 4.
Three studies evaluated HRQOL among active TB
patients at three time points roughly at the beginning of TB
treatment, at the end of the initial intensive phase of
treatment, and well into the continuation phase of treatment
or at the end of treatment [13–15, 32]. In all three studies,
the greatest improvement in HRQOL occurred during the
first 2–3 months of treatment. Based on the previously
published minimum important difference of 4 points for the
SGRQ, 94 % of subjects reported by Maguire et al. [27, 32]
had a meaningful improvement between diagnosis and
2 months of treatment; between 2 and 6 months of
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treatment, 80 % of these subjects reported meaningful
improvement.
Kruijshaar et al. [29] used 3 instruments to evaluate
HRQOL among patients treated for active TB at diagnosis
and after 2 months of treatment. Although there was some
improvement in HRQOL as indicated by the effect sizes for
the Short Form 36 (SF-36) Physical Component Score
(PCS) and the State-Trait Anxiety Inventory Short Form
(STAI-6), these effects sizes did not indicate meaningful
change in HRQOL. However, meaningful improvements in
HRQOL were suggested by the effect sizes of the SF-36
Mental Component Score (MCS) and the Center for Epi-
demiologic Studies Depression Scale (CES-D) [29].
Marra et al. [33] measured HRQOL with the SF-36 and
the Beck Depression Inventory (BDI) among patients
treated for active TB at their diagnosis and after complet-
ing 6 months treatment. There was no meaningful change
indicated by the effects size for all three instruments. Our
calculations match the conclusion made by Marra et al. [33,
42], who used a standard of the difference in the two mean
scores of at least 5 points to identify meaningful changes in
mean HRQOL scores.
Marra et al. [33] also provided longitudinal measures of
the SF-36 and the BDI among subjects treated for LTBI.
None of the effect sizes indicated meaningful changes in
HRQOL. SF-36 results were confirmed by the standard of
using a 5-point cut-off of mean scores to determine
meaningful changes in HRQOL [42].
Appendix 4
The following information summarizes results of 4 studies
assessing HRQOL among subjects with post-TB sequelae,
i.e, no longer active TB disease [9, 10, 19, 37, 40, 57, 58].
These patients developed chronic alveolar hypoventilation
and were subsequently placed on home mechanical venti-
lation (HMV) (Table 7 in Appendix). Five HRQOL
instruments were used among these four studies.
The GHQ-12 was used in 2 studies; in both studies, post-
TB sequelae patients rated their HRQOL better than the
comparison groups of patients on HMV due to other dis-
eases [9, 10, 19, 37, 40]. HRQOL among these post-TB
sequelae patients was, however, rated lower than the active
TB subjects and comparison groups assessed by Aydin
et al. and Aghanwa et al. [1, 2] with the same question-
naire. Patients with post-TB sequelae are much older than
the active TB patients evaluated by Aydin et al. and Ag-
hanwa et al., and thus, their HRQOL may be affected by
age and other factors.
Pehrsson et al. [40] found that the group of post-TB
sequelae patients (compared to the group of subjects also
on HMV due to other diseases) reported better HRQOL
according to their mean HAD score for anxiety, but worse
HRQOL according to their mean HAD scores for
depression.
Using the Mood Adjective Checklist Short Form
(MACL), Dellborg et al. [9, 10, 19, 37] observed notice-
ably worse HRQOL among the patients on HMV due to
post-TB sequelae compared to the group of patients on
HMV due to other diseases. The range of mean MACL
domain scores found by Pehrsson et al. [40] did not,
however, indicate a difference in HRQOL between these 2
groups of patients.
Dellborg et al. and Pehrsson et al. [9, 10, 19, 37, 40] also
used the Sickness Impact Profile (SIP) to evaluate HRQOL
of patients on HMV. Dellborg et al. found worse mean SIP
scores among the group of subjects on HMV due to post-
TB sequelae compared to patients on HMV due to other
diseases, with the former group exceeding the score cut-off
of severe dysfunction [9, 10, 19, 37]. On the contrary, the
mean SIP scores in the study by Pehrsson et al. [40] indi-
cated that the post-TB sequelae patients rated their
HRQOL better than the comparators.
Two studies used the Severe Respiratory Insufficiency
Questionnaire (SRI) [31, 57, 58]. One study found worse
HRQOL among subjects on HMV due to post-TB sequelae
compared to subjects on HMV due to other diseases [57, 58].
The second study found that patients on HMV due to post-TB
sequelae rated their HRQOL slightly better than patients on
HMV for other illnesses [31]. However, there was only a
7-point difference between the highest mean score and lowest
mean score of these patient groups across the 2 studies.
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